Table 3.
Bevacizumab in epithelial ovarian carcinoma (Phase II).
Variable | Cannistra (n = 44) (%) |
Garcia* (n = 70) (%) |
Burger (n = 62) (%) |
---|---|---|---|
Previous regimens | |||
1 | 100 | 34 | |
2 | 52 | ||
3 | 48 | ||
Response rate | |||
CR | 0 | 0 | 3 |
PR | 16 | 24 | 18 |
GI perforations | 11 | 6 | 0 |
Arterial thrombosis | 7 | 4 | 0 |
Bevacizumab-related deaths | 7 | 4 | 0 |
Ref. | [8] | [9] | [7] |
Combined with oral cyclophosphamide.
CR: Complete response; GI: Gastrointestinal; PR: Partial response.